BeiGene, Ltd.

NasdaqGS:BGNE Stock Report

Market Cap: US$19.3b

BeiGene Management

Management criteria checks 2/4

BeiGene's CEO is John Oyler, appointed in Jan 2010, has a tenure of 14.92 years. total yearly compensation is CN¥134.33M, comprised of 4.6% salary and 95.4% bonuses, including company stock and options. directly owns 3.48% of the company’s shares, worth $671.50M. The average tenure of the management team and the board of directors is 3.3 years and 4.3 years respectively.

Key information

John Oyler

Chief executive officer

CN¥134.3m

Total compensation

CEO salary percentage4.6%
CEO tenure14.9yrs
CEO ownership3.5%
Management average tenure3.3yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US

Dec 01

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

Nov 06

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

Aug 14
Analysts Just Made An Incredible Upgrade To Their BeiGene, Ltd. (NASDAQ:BGNE) Forecasts

BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

Aug 09
BeiGene, Ltd. (NASDAQ:BGNE) Shares Fly 27% But Investors Aren't Buying For Growth

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

May 30
We Think Some Shareholders May Hesitate To Increase BeiGene, Ltd.'s (NASDAQ:BGNE) CEO Compensation

Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

Apr 21
Is BeiGene (NASDAQ:BGNE) Using Too Much Debt?

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

Mar 08

BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

Jan 31
BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price

CEO Compensation Analysis

How has John Oyler's remuneration changed compared to BeiGene's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CN¥6b

Jun 30 2024n/an/a

-CN¥4b

Mar 31 2024n/an/a

-CN¥6b

Dec 31 2023CN¥134mCN¥6m

-CN¥6b

Sep 30 2023n/an/a

-CN¥7b

Jun 30 2023n/an/a

-CN¥13b

Mar 31 2023n/an/a

-CN¥13b

Dec 31 2022CN¥124mCN¥6m

-CN¥14b

Sep 30 2022n/an/a

-CN¥15b

Jun 30 2022n/an/a

-CN¥14b

Mar 31 2022n/an/a

-CN¥12b

Dec 31 2021CN¥106mCN¥5m

-CN¥9b

Sep 30 2021n/an/a

-CN¥9b

Jun 30 2021n/an/a

-CN¥9b

Mar 31 2021n/an/a

-CN¥8b

Dec 31 2020CN¥94mCN¥5m

-CN¥11b

Sep 30 2020n/an/a

-CN¥10b

Jun 30 2020n/an/a

-CN¥10b

Mar 31 2020n/an/a

-CN¥8b

Dec 31 2019CN¥88mCN¥5m

-CN¥7b

Sep 30 2019n/an/a

-CN¥6b

Jun 30 2019n/an/a

-CN¥5b

Mar 31 2019n/an/a

-CN¥5b

Dec 31 2018CN¥192mCN¥4m

-CN¥5b

Sep 30 2018n/an/a

-CN¥3b

Jun 30 2018n/an/a

-CN¥2b

Mar 31 2018n/an/a

-CN¥923m

Dec 31 2017CN¥67mCN¥3m

-CN¥606m

Compensation vs Market: John's total compensation ($USD18.41M) is above average for companies of similar size in the US market ($USD12.85M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Oyler (56 yo)

14.9yrs

Tenure

CN¥134,331,046

Compensation

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009....

Leadership Team

NamePositionTenureCompensationOwnership
John Oyler
Co-Founder14.9yrsCN¥134.33m3.48%
$ 671.5m
Xiaobin Wu
President & COO6.6yrsCN¥78.08m0.056%
$ 10.7m
Xiaodong Wang
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder14.9yrsCN¥31.35m0.73%
$ 141.1m
Chan Lee
General Counsel & Senior VP2.4yrsCN¥28.74m0.017%
$ 3.3m
Wang Lai
Global Head of R&Dno dataCN¥51.93m0.13%
$ 24.9m
Aaron Rosenberg
CFO & Principal Financial Officerless than a yearno datano data
Titus Ball
VP & Chief Accounting Officerless than a yearno data0.0033%
$ 644.5k
Liza Heapes
Head of Investor Relationsno datano datano data
Yang Ji
Chief Compliance Officer1.2yrsno datano data
Yan Qi
Senior VP & Head of Public Affairs - Greater China3.9yrsno datano data
Mark Lanasa
Senior VP & Chief Medical Officer for Solid Tumors2.8yrsno datano data
Graham Hardiman
Global Head of Human Resources3.8yrsno datano data

3.3yrs

Average Tenure

56yo

Average Age

Experienced Management: BGNE's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Oyler
Co-Founder14.2yrsCN¥134.33m3.48%
$ 671.5m
Xiaodong Wang
Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder8.8yrsCN¥31.35m0.73%
$ 141.1m
Steven Young
Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board3.7yrsno datano data
Michael Goller
Independent Non-Executive Director & Member of the Scientific Advisory Committee9.7yrsCN¥3.42m0.0046%
$ 879.9k
Corazon Sanders
Independent Non-Executive Director & Member of Scientific Advisory Committee4.3yrsCN¥3.56m0.0022%
$ 416.8k
Anthony Hooper
Independent Non-Executive Director4.9yrsCN¥3.64m0.0027%
$ 522.9k
Shalini Sharp
Directorless than a yearno datano data
Alessandro Riva
Co-Chairman of Scientific Advisory Committee & Independent Non-Executive Director2.8yrsCN¥3.49m0.0021%
$ 412.9k
Olivier Brandicourt
Independent Non-Executive Directorless than a yearno data0%
$ 0
Ranjeev Krishana
Independent Lead Director10.2yrsCN¥3.46m0.0046%
$ 879.9k
Margaret Han Dugan
Member of Scientific Advisory Board & Independent Non-Executive Director2.8yrsCN¥3.62m0.0021%
$ 412.9k

4.3yrs

Average Tenure

62yo

Average Age

Experienced Board: BGNE's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:13
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BeiGene, Ltd. is covered by 56 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Michael MengBOCI Research Ltd.
Yonglin YanBOCI Research Ltd.